Aerska, a startup developing treatments to silence the problematic genes that cause various brain diseases, has raised $39 ...

The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...

The new year brought a slew of new faces in the pharma and biotech world, especially in the top jobs, with a number of CEO ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the industry—and Washington—are rethinking the risks.

Eli Lilly will acquire Orna Therapeutics for up to $2.4 billion to gain access to the Watertown biotech's circular RNA technology platform.

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of 2020 and 2021 and an anticipated stock recovery in 2024 failed to materialise.

The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...

Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) announced that its proprietary nasal spray influenza attenuated live vaccine, DIFF-flu, has recently received clinical trial approval ...

Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market. | Immunology biotech ...

FAR Biotech, a computational drug discovery company, has officially relocated to Wisconsin. The move marks a significant milestone for the company, which is collaborating with the University ...

UK biotech showed resilience in a tough 2025 for healthcare funding, suggesting investor interest could grow in 2026.

Department of Economic & Community Development Commissioner Daniel O'Keefe speaks at the BioCT legislative breakfast in New Haven on Jan. 27, 2025. Monday morning's annual legislative breakfast hosted ...